Pharma & Biotech

As BioNTech navigates a pivotal transition away from its pandemic-era revenue, the company is asking its shareholders to approve a...

Medical technology giant Abbott Laboratories has made a decisive strategic pivot, solidifying its position in the high-growth field of precision...

China Pharma Holdings has provided investors with preliminary insights into its performance, despite missing the official deadline for filing its...

This week, the Danish pharmaceutical giant Novo Nordisk executed a multi-faceted strategic push across three distinct areas. The company launched...

Bayer faces a period of significant transition as declining revenues from its former blockbuster drugs compel urgent strategic action. The...

Following a period of aggressive expansion, Bruker is now entering a critical phase where execution is paramount. The company's recent...

Amidst a challenging year that includes projected adjusted revenue declines of up to 13%, Novo Nordisk is fortifying its competitive...

Investors in Replimune are positioning for a potential resolution to a prolonged period of uncertainty. The company's stock price advanced...

BioNTech is methodically moving beyond its pandemic legacy. A series of recent strategic decisions—from facility closures and halted trials to...

Sangamo Therapeutics finds itself navigating a complex landscape of operational progress against a backdrop of challenging financial performance. Recent developments...